Company performance
Add to research
Current Price
as of Apr 24, 2025$120.54
P/E Ratio
N/A
Market Cap
$28.93B
Description
Add to research
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Metrics
Add to research
Overview
- HQMainz, RP
- SectorHealth Technology
- IndustryBiotechnology
- TickerBNTX
- Price$120.54+4.97%
Trading Information
- Market cap$28.93B
- Float98.44%
- Average Daily Volume (1m)1,219,875
- Average Daily Volume (3m)947,490
- EPS-$2.99
Company
- Revenue$2.98B
- Rev growth (1yr)-27.92%
- Net income-$719.65M
- Gross margin80.32%
- EBITDA margin-12.55%
- EBITDA-$373.62M
- EV$10.77B
- EV/Revenue3.62
- P/EN/A
- P/S9.74
- P/B1.44
- Debt/Equity1.31
Documents
Add to research
Factset Street Account
Earnings Calls
Factset